Argenx to buy Forte Biosciences for about $2.2 billion
FBRX•Argenx agrees to acquire Forte Biosciences
July 27 (Reuters) - Belgian-Dutch immunology company argenx ARGX.BR will buy Forte Biosciences FBRX.O to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
Argenx will pay $77 a share in cash, valuing the U.S. drug developer at about $2.2 billion, in a deal that gives it a first-in-class anti-CD122 antibody that has shown early promise in vitiligo and celiac disease.
